Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Brief Summary: The primary objective of this study is to determine whether reslizumab is more effective than placebo in reducing the number of clinical asthma exacerbations (CAEs) in patients with eosinophilic asthma.


Options:
A: Arm Label: Placebo (for Dupilumab 200 mg) q2w; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Arm Label: Dupilumab 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Arm Label: Placebo (for Dupilumab 300 mg) q2w; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Inhaled corticosteroid (ICS) therapy, Drug: Albuterol/Salbutamol, Drug: Levalbuterol/Levosalbutamol | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w | Intervention Type: DRUG; Name: Inhaled corticosteroid (ICS) therapy; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w | Intervention Type: DRUG; Name: Albuterol/Salbutamol; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w | Intervention Type: DRUG; Name: Levalbuterol/Levosalbutamol; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Placebo (for Dupilumab 200 mg) q2w, Placebo (for Dupilumab 300 mg) q2w
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-IgE antibody omalizumab or placebo | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Anti-IgE antibody omalizumab or placebo | Intervention Type: DRUG; Name: Anti-IgE antibody omalizumab or placebo; Assigned to Arm(s): 1, 2
D: Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Arm Label: Dupilumab 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Arm Label: Dupilumab 300 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: placebo, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Arm Label: Dupilumab 200 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: placebo, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Arm Label: Placebo q2w; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: ICS/LABA therapy, Drug: Salbutamol/albuterol, Drug: Levosalbutamol/levalbuterol | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 200 mg q4w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Dupilumab 200 mg q4w, Dupilumab 300 mg q4w, Placebo q2w | Intervention Type: DRUG; Name: ICS/LABA therapy; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 200 mg q4w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo q2w | Intervention Type: DRUG; Name: Salbutamol/albuterol; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 200 mg q4w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo q2w | Intervention Type: DRUG; Name: Levosalbutamol/levalbuterol; Assigned to Arm(s): Dupilumab 200 mg q2w, Dupilumab 200 mg q4w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo q2w

Answer: B